This company listing is no longer active
Deinove (ALDEI) Stock Overview
DEINOVE SA, a biotechnology company, discovers, develops, and produces compounds from microbials for the health, nutrition, and cosmetics industries worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ALDEI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
An Undervalued 3.3Moz Gold Project in Canada
Key takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.Read more
Deinove SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.026 |
| 52 Week High | €0.31 |
| 52 Week Low | €0.0062 |
| Beta | 0.78 |
| 1 Month Change | 0% |
| 3 Month Change | 10.42% |
| 1 Year Change | -91.12% |
| 3 Year Change | -96.30% |
| 5 Year Change | -99.29% |
| Change since IPO | -99.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALDEI | FR Chemicals | FR Market | |
|---|---|---|---|
| 7D | 0% | 4.1% | 3.5% |
| 1Y | -91.1% | 3.8% | 5.1% |
Return vs Industry: ALDEI underperformed the French Chemicals industry which returned 4% over the past year.
Return vs Market: ALDEI underperformed the French Market which returned 11.4% over the past year.
Price Volatility
| ALDEI volatility | |
|---|---|
| ALDEI Average Weekly Movement | n/a |
| Chemicals Industry Average Movement | 6.0% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in FR Market | 10.5% |
| 10% least volatile stocks in FR Market | 2.9% |
Stable Share Price: ALDEI has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ALDEI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 44 | Alexis Rideau | www.deinove.com |
DEINOVE SA, a biotechnology company, discovers, develops, and produces compounds from microbials for the health, nutrition, and cosmetics industries worldwide. The company’s pipeline includes DNV3837, an antibiotic, which is in the Phase II clinical trial for the treatment of Clostridioides difficile infections. It also offers Dual-Acting Small Molecule Antibiotics, a class of dual activity antibiotics that develops a new class of 2-in-1 molecules whose structure results from the combination of two active antibiotic moieties.
Deinove SA Fundamentals Summary
| ALDEI fundamental statistics | |
|---|---|
| Market cap | €843.07k |
| Earnings (TTM) | -€7.37m |
| Revenue (TTM) | €241.00k |
Is ALDEI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALDEI income statement (TTM) | |
|---|---|
| Revenue | €241.00k |
| Cost of Revenue | €3.91m |
| Gross Profit | -€3.67m |
| Other Expenses | €3.71m |
| Earnings | -€7.37m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | -1,521.58% |
| Net Profit Margin | -3,058.92% |
| Debt/Equity Ratio | -127.0% |
How did ALDEI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/08 10:10 |
| End of Day Share Price | 2023/01/10 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Deinove SA is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jonas Peciulis | Edison Investment Research |
| Arnaud Guérin | Portzamparc BNP Paribas |
| Pierre Vaurice | TPICAP Midcap |